PlasmaGen Biosciences Secures Rs 50 Crore To Drive Global Expansion

WOWLY- Your AI Agent Apr 02, 2026 950 Views

PlasmaGen Biosciences has raised Rs 50 crore to strengthen its international presence and expand its portfolio of plasma-derived therapeutics. The funding will support global market entry, enhance manufacturing capabilities, and accelerate innovation in specialty care therapies, positioning the Bengaluru-based biopharma company for sustainable growth.

PlasmaGen Biosciences, a Bengaluru-based biopharmaceutical company specializing in plasma protein and specialty care therapies, has announced securing Rs 50 crore in fresh funding. The investment is part of the company’s broader strategy to expand into global markets and scale its operations. Founded in 2010, PlasmaGen has steadily built a reputation in India’s healthcare sector, focusing on plasma-derived pharmaceutical products that address critical medical needs.

Key highlights from the announcement include

PlasmaGen Biosciences raised Rs 50 crore to support international expansion and strengthen its product portfolio.
The company specializes in plasma protein therapies and has a strong presence in India’s specialty care market.
Funds will be utilized to enhance manufacturing capabilities and accelerate innovation in plasma-derived therapeutics.
PlasmaGen has raised over Rs 600 crore in total funding since its inception, reflecting strong investor confidence.
The company’s valuation stands at approximately Rs 795 crore, backed by investors including Eight Roads Ventures and F-Prime Capital.
Global expansion plans include entering emerging markets with high demand for plasma-based healthcare solutions.
Industry experts note that the funding underscores growing interest in biopharma firms addressing niche healthcare needs.
PlasmaGen aims to leverage its expertise to deliver accessible and affordable therapies worldwide.

The fresh capital infusion marks a significant milestone for PlasmaGen Biosciences as it transitions from a domestic leader to a global player in plasma-derived therapeutics. With rising demand for specialty care solutions and supportive investor backing, the company is well-positioned to expand its footprint and contribute to global healthcare innovation.

Sources: MSN, Tracxn, PR Newswire

Stay Ahead – Explore Now! Concord Biotech Passes ANVISA Audit at Limbasi API Facility